IRMD Stock Analysis: Buy, Sell, or Hold?
IRMD - iRadimed Corporation
$97.88
-1.30 (-1.31%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
11d
Get Alerted When IRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IRMD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: IRMD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$80.79
Based on 8.9% avg growth
INTRINSIC VALUE TODAY
$50.16
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRMD is currently trading at $97.88, which is considered slightly low relative to its 30-day fair value range of $97.05 to $101.43. The stock's valuation (Forward PE: 46.8) is in line with its historical norms (45.3). At these levels, the market is pricing in 1.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IRMD is in a strong uptrend. The price is currently testing key support at $96.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRMD is in a strong uptrend. The price is currently testing key support at $96.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$97.05 -
$101.43
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($99.00)
- NEUTRAL: Market pricing in 1.1% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$97.05 -
$101.43
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$4.31
(4.4%)
Support & Resistance Levels
Support Level
$96.46
Resistance Level
$104.93
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
46.78
Wall Street Target
$99.00
(-0.2%)
Revenue Growth (YoY)
15.7%
Earnings Growth (YoY)
7.9%
Profit Margin
26.3%
Valuation Premium vs History
+1.1% premium
PE vs Historical
46.8 vs 45.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.1%
(market-implied from PE analysis)
1-Year Target
$100.27
(+1%)
2-Year Target
$101.37
(+2%)
3-Year Target
$102.49
(+3%)
3-Yr Target (if PE normalizes)
(PE: 47→45)
PE COMPRESSION
$99.24
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.8, Growth: 13.7%)
$145.68
(+47%)
Base:
(SPY PE: 22.3, Growth: 13.7%)
$69.44
(-30%)
Bear:
(PE: 19.0, Growth: 13.7%)
$59.02
(-41%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (59x PE), but valuation improves significantly next year (47x PE) as earnings recover.
Trailing PE: 59.35 | Current EPS (TTM): $1.65
Bull Case
$138.39
(+41%)
Analyst growth 28.5%, PE expands to 65.3
Base Case
$125.81
(+29%)
Market implied 28.5%, PE stable at 59.4
Bear Case
$66.59
(-32%)
Severe decline -20.0%, PE contracts to 50.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 11:32 PM ET
Data refreshes hourly during market hours. Next update: 12:32 AM
Data refreshes hourly during market hours. Next update: 12:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger E Susi
SELL
5000 shares
2025-10-21
Roger E Susi
SELL
5000 shares
2025-10-13
Roger E Susi
SELL
5000 shares
2025-10-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$427 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
Advanced IRMD Option Strategies
Professional options setups generated by AI based on today's IRMD price and gamma walls.
